z-logo
open-access-imgOpen Access
Temporal variation in antibiotic environments slows down resistance evolution in pathogenic Pseudomonas aeruginosa
Author(s) -
Roemhild Roderich,
Barbosa Camilo,
Beardmore Robert E.,
Jansen Gunther,
Schulenburg Hinrich
Publication year - 2015
Publication title -
evolutionary applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.776
H-Index - 68
ISSN - 1752-4571
DOI - 10.1111/eva.12330
Subject(s) - biology , doripenem , antibiotics , experimental evolution , cefsulodin , pseudomonas aeruginosa , antibiotic resistance , adaptation (eye) , drug resistance , population , gentamicin , genetics , microbiology and biotechnology , bacteria , gene , medicine , environmental health , imipenem , neuroscience , ceftazidime
Antibiotic resistance is a growing concern to public health. New treatment strategies may alleviate the situation by slowing down the evolution of resistance. Here, we evaluated sequential treatment protocols using two fully independent laboratory‐controlled evolution experiments with the human pathogen Pseudomonas aeruginosa PA 14 and two pairs of clinically relevant antibiotics (doripenem/ciprofloxacin and cefsulodin/gentamicin). Our results consistently show that the sequential application of two antibiotics decelerates resistance evolution relative to monotherapy. Sequential treatment enhanced population extinction although we applied antibiotics at sublethal dosage. In both experiments, we identified an order effect of the antibiotics used in the sequential protocol, leading to significant variation in the long‐term efficacy of the tested protocols. These variations appear to be caused by asymmetric evolutionary constraints, whereby adaptation to one drug slowed down adaptation to the other drug, but not vice versa. An understanding of such asymmetric constraints may help future development of evolutionary robust treatments against infectious disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here